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 In recent years, there has been increased appreciation regarding the potential 24 
outcomes of patients following episodes of acute kidney injury.  While a majority of 25 
patients surviving an initial episode of AKI recover “normal” renal function, persistent 26 
structural alterations following repair responses can result in development of CKD or 27 
ESRD  (5).   28 
While clinical studies have not provided a clear understanding of the 29 
mechanisms of CKD progression following AKI, animal models of injury have been used 30 
to identify persistent alterations in renal structure following injury that appear to set in 31 
motion progressive CKD.  For example, injury-induced changes in the interstitium, such 32 
as activation of myofibroblasts following renal ischemia/reperfusion, contribute to the 33 
development of interstitial fibrosis while inflammation, profibrotic growth factors from 34 
damaged tubules, and peritubular capillary rarefaction may amplify the fibrotic process 35 
(3).   With regard to rarefaction, the reduction of peritubular capillary density has been 36 
proposed to augment hypoxia and fuel interstitial fibrosis (3).  Interestingly, reductions in 37 
peritubular capillary density have been shown in renal biopsies of patients with CKD, 38 
and correlate with reduced renal survival (7).  39 
 However, there remains many gaps in our knowledge about the relative 40 
contribution of these factors since animal studies of AKI to CKD do not routinely 41 
measure renal function (i.e. GFR) directly, but rather use surrogate markers of tissue 42 
injury and GFR. Alterations in factors such as plasma creatinine or the presence of 43 
interstitial fibrosis may not reflect true GFR, making conclusions about progression 44 
speculative.  Moreover, there has been little investigation in other models of AKI outside 45 
of ischemia reperfusion, such as those which use nephrotoxic agents with different 46 
pathophysiology.  47 
 In the current issue of American Journal of Physiology- Renal Physiology, 48 
Menshikh et al., publish a careful comparison of different mouse models of AKI and 49 
analyzed different features of chronic injury and progression (8).  The authors used a 50 
nephrotoxic injury model using a repetitive cisplatin dosing approach and compared this 51 
with a rhabdomyolysis model induced by intramuscular injection of glycerol. These were 52 
both compared with a more widely-utilized model of unilateral I/R injury followed by 53 
delayed contralateral nephrectomy; this model has evolved to circumvent problems 54 
associated with high mortality rates in mice subjected to severe bilateral I/R (8, 9).   In 55 
addition to comparing renal fibrosis and capillary density, the authors also evaluated 56 
GFR by performing sequential sinistrin clearance using a transcutaneous fluorescence 57 
technique (10).  This comprehensive approach provides food for thought on the 58 
important aspects of injury which may most closely associate with progressive CKD. 59 
 Using these models, different aspects of chronic injury were observed. For 60 
example, rhabdomyolysis resulted in prominent interstitial fibrosis, but was not 61 
associated with significant decline in peritubular capillary density or GFR relative to 62 
controls.  The repetitive-cisplatin model resulted in only moderate interstitial fibrosis but 63 
a significant decline in GFR.  In addition, the repetitive cisplatin dosing model was 64 
associated with a prominent reduction in peritubular capillary density (8).  Thus, results 65 
from two different models revealed a dissociation in capillary rarefaction and interstitial 66 
fibrosis, both of which are generally correlated with, and considered highly predictive of 67 
kidney failure (1, 7).  Moreover, the results would suggest that capillary rarefaction is 68 
most closely aligned with progression based on loss of GFR. 69 
 These observations raise a number of questions.  For example, why would loss 70 
of peritubular capillary density result in a loss of glomerular filtration?  As mentioned, 71 
previous hypotheses regarding peritubular capillary rarefaction invoke its potential role 72 
in hypoxia to promote interstitial fibrosis (3).  However, since fibrosis is not prominent in 73 
the cisplatin model, this is not likely the explanation.  It should be noted that studies 74 
from other laboratories have demonstrated an overall atrophy of renal tubules and an 75 
uncapping of glomeruli following repetitive cisplatin injection.  Indeed, the degree of 76 
uncapped glomeruli was also shown to be correlated with loss of GFR (11).  Whether or 77 
not the sustained tubular injury and lack of tubular repair is due to capillary rarefaction, 78 
or conversely, whether the sustained capillary rarefaction is attributable to loss of 79 
nephrons has not yet been investigated.   80 
 A second interesting aspect of the current studies relates to the comparison of 81 
these models with that of unilateral I/R and delayed nephrectomy.  When short-term 82 
recovery periods of 4 weeks were examined, both fibrosis and capillary loss were 83 
associated with reduced GFR. Surprisingly, when recovery was extended to 12 weeks, 84 
the authors observed an apparent reversal of both GFR and capillary density, while 85 
renal fibrosis was persistent. This is a fascinating result that deserves additional 86 
attention as reversal of capillary density has not been prominently described.  Indeed 87 
our group had initially suggested that capillary loss is permanent and vascular repair 88 
capacity is minimal following AKI (4).  This may be due in part to intrinsically low levels 89 
of proliferative and angiogenic activity of renal endothelial cells (2).  Recently, Dang et 90 
al., suggested that FoxO1 is expressed prominently in renal EC, and that this factor 91 
conveys suppressed angiogenic potential in these cells (6). Thus, if the reversal of 92 
CD31+ vessel staining observed by Menshikh et al. reflects actual angiogenesis, altered 93 
intracellular signaling induced by the delayed nephrectomy could allow for the activation 94 
of an angiogenic response in kidney ECs which typically lack regenerative potential. 95 
However, some caveats should be considered.  Since only CD31 staining was used for 96 
measuring capillaries, it is fair to consider whether the results represent detection of 97 
dormant EC in which low CD31 expression is reactivated in response to contralateral 98 
nephrectomy.  This does not diminish the importance of this overall observation 99 
however, as the association with vessel staining and reversal of GFR represent a 100 
compelling advance in understanding the link to progression.  101 
Finally, the experimental approach using different models should prompt all 102 
investigators to recognize that not all models are equal.  Studies such as the one 103 
highlighted here provide perspective on different causes of injury resulting in various 104 
long-term outcomes, which is especially important since the etiology of patients is 105 
diverse. While similarities may exist, analysis of differences between models may allow 106 
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